癌变·畸变·突变2026，Vol.38Issue(2)：142-149,155,9.DOI:10.3969/j.issn.1004-616x.2026.02.009
IGHG1和TMSB10蛋白表达与HER2阳性乳腺癌新辅助治疗效果及预后的关系
Relationship between expression of IGHG1 and TMSB10 proteins and neoadjuvant therapy efficacy in HER2-positive breast cancer
孙雪 1黄诗禄 2焦纪伟 3廖勇 3邱前程 3洪良利3
作者信息
- 1. 汕头大学医学院第一附属医院,广东 汕头 515041||汕头大学医学院,广东汕头 515041
- 2. 中山大学肿瘤防治中心,广东 广州 510060
- 3. 汕头大学医学院第一附属医院,广东 汕头 515041
- 折叠
摘要
Abstract
OBJECTIVE:To investigate correlations between protein expression of immunoglobulin heavy constant gamma 1(IGHG1)and thymosin β10(TMSB10)with pathological complete response(pCR)and Miller-Payne(MP)grading following neoadjuvant therapy(NAT)in patients with human epidermal growth factor receptor 2(HER2)-positive breast cancer,and to evaluate their predictive value.METHODS:Data of 242 HER2-positive breast cancer cases were obtained from the NAT dataset GSE243375 in the GEO database.Differentially expressed genes related to pCR were screened through differential expression analysis,LASSO regression,and support vector machine recursive feature elimination(SVM-RFE).Pathological tissue paraffin blocks and clinicopathological data were collected from 108 HER2-positive breast cancer patients who received NAT.The chi-square test was used to analyze correlations between expression of these two proteins and clinicopathological characteristics.The Mann-Whitney U test was employed to compare differences in protein expression levels between the pCR group and the non-pCR group.Spearman rank correlation analysis was performed to evaluate correlations between their expression and MP grade.Furthermore,binary logistic regression and ordinal logistic regression were used to adjust for confounding variables and to analyze independent predictive values of IGHG1 and TMSB10 for pCR and MP grade.RESULTS:Bioinformatics analysis identified 10 differentially expressed genes related to pCR after NAT in HER2-positive breast cancer.The AUC values for predicting pCR by IGHG1 and TMSB10 were 0.626 and 0.618,respectively.Immunohistochemical results showed that TMSB10 was mainly expressed in the cytoplasm of breast cancer tumor cells,presenting brown-yellow granular staining.IGHG1 was mainly expressed in the cytoplasm of breast cancer tumor cells,showing diffuse or focal brown-yellow granular staining,with occasionally positive expression on the cell membrane.Univariate analysis revealed that expression levels of TMSB10 were significantly higher in the pCR group than in the non-pCR group(P=0.038),and the proportion of IGHG1 high expression in the pCR group(15.3％)was also significantly higher than that in the non-pCR group(2.0％)(P=0.043).Multivariate Logistic regression analysis showed that TMSB10 was an independent predictor of increased MP grade[OR=1.232,95％CI(1.060,1.431),P=0.006],and IGHG1 was also an independent predictor of increased MP grade[OR=1.434,95％CI(1.028,2.000),P=0.034].The combined prediction AUC value for pCR by both indicators was 0.660[95％CI(0.557,0.763)],which was superior to a single indicator.CONCLUSION:IGHG1 was shown to be an independent predictor of increased MP grade after neoadjuvant therapy in HER2-positive breast cancer,and its high expression was significantly associated with higher pCR rates.TMSB10 was an independent predictor of pCR and increased MP grade.IGHG1 and TMSB10 can be considered to be potential biomarkers for predicting efficacy of NAT in HER2-positive breast cancer.The combined application of IGHG1 and TMSB10 could improve accuracy of predicting the efficacy of NAT in HER2-positive breast cancer.关键词
乳腺癌/新辅助治疗/免疫球蛋白重链1/胸腺素β10Key words
breast cancer/neoadjuvant therapy/IGHG1/TMSB10分类
医药卫生引用本文复制引用
孙雪,黄诗禄,焦纪伟,廖勇,邱前程,洪良利..IGHG1和TMSB10蛋白表达与HER2阳性乳腺癌新辅助治疗效果及预后的关系[J].癌变·畸变·突变,2026,38(2):142-149,155,9.
